LABELS · 7dcc9b87-0aa4-4a00-aced-96be3553e8ac

Ibrance

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-07-02
Captured: 2026-09-09T23:37:51.659493+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

Full extracted label fields

application numbers

NDA207103

boxed warning exact

brand names

Ibrance

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07

generic names

PALBOCICLIB

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

indications and usage exact

1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

indications and usage tables exact

is original packager

true

manufacturer names

Pfizer Laboratories Div Pfizer Inc

matched search terms

cancer

package ndcs

0069-0187-21
0069-0188-21
0069-0189-21

product ndcs

0069-0187
0069-0188
0069-0189

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage ( 1.1 , 1.2 ) 6/2026 Dosage and Administration ( 2.1 , 2.2 ) 6/2026

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

1601380
1601386
1601388
1601390
1601392
1601394

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00400.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA207103

brand names

Ibrance

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 264
end exclusive: true
exact text: 1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an arom
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 0

current approval status

not_reconciled

duplicate text group

dup-8541af10b458f41a7338

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-b087a4ddbe984ac0d255

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

end: 63
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 64
end exclusive: true
exact text: 1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated:
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

NDA207103

brand names

Ibrance

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 606
end exclusive: true
exact text: 1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic brea
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 0

current approval status

not_reconciled

duplicate text group

dup-20bdd8454d2783a45fd0

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-333c4ed0b643615bdebe

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

end: 63
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 32

qualifier mentions

context exact
• for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
102
end exclusive
true
exact text
adult patients
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
88
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as ini
kind
biomarker
polarity
not_inferred
span
end
226
end exclusive
true
exact text
HER2)-negative advanced or metastatic breast
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
182
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine
kind
stage_or_setting
polarity
not_inferred
span
end
240
end exclusive
true
exact text
advanced or metastatic breast cancer in com
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
197
context exact
ptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression
kind
regimen
polarity
not_inferred
span
end
318
end exclusive
true
exact text
in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
234

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 406
end exclusive: true
exact text: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy.
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 65

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · unclassified context

application numbers

NDA207103

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 614
end exclusive: true
exact text: r metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cance
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 207

current approval status

not_reconciled

duplicate text group

dup-aafc5f7803dc07c28844

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-c01561f90591571f1e5f

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 414
end exclusive: true
exact text: ( 1.1 )
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 407

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

NDA207103

brand names

Ibrance

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 927
end exclusive: true
exact text: atic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metast
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 215

current approval status

not_reconciled

duplicate text group

dup-8af3c96640bbbcfb13a2

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-60b19720e4d276b5699a

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

end: 63
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 32

qualifier mentions

context exact
nation with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER
kind
age
polarity
not_inferred
span
end
499
end exclusive
true
exact text
adult patients
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
485
context exact
r the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic
kind
biomarker
polarity
not_inferred
span
end
541
end exclusive
true
exact text
PIK3CA -mutated
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
526
context exact
nts with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected
kind
biomarker
polarity
not_inferred
span
end
569
end exclusive
true
exact text
HER2-negative
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
556
context exact
A -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrenc
kind
biomarker
polarity
not_inferred
span
end
615
end exclusive
true
exact text
metastatic breast cancer
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
591
context exact
ine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrenc
kind
stage_or_setting
polarity
not_inferred
span
end
615
end exclusive
true
exact text
locally advanced or metastatic breast cancer
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
571
context exact
uthorized test, following recurrence on or after completing adjuvant endocrine therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
726
end exclusive
true
exact text
adjuvant endocrine therapy
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
700
context exact
• in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test,
kind
regimen
polarity
not_inferred
span
end
596
end exclusive
true
exact text
in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metas
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
417

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 727
end exclusive: true
exact text: • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy.
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 415

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · unclassified context

application numbers

NDA207103

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 935
end exclusive: true
exact text: K3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic bre
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 528

current approval status

not_reconciled

duplicate text group

dup-aafc5f7803dc07c28844

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-1f49c08f51c9a9c0a134

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 735
end exclusive: true
exact text: ( 1.1 )
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 728

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA207103

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1176
end exclusive: true
exact text: tated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negati
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 536

current approval status

not_reconciled

duplicate text group

dup-a691b77c46bf128980a8

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-6eeeccaf2a2724358f9c

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

Source null

qualifier mentions

context exact
mab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metasta
kind
age
polarity
not_inferred
span
end
868
end exclusive
true
exact text
adult patients
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
854
context exact
e maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment.
kind
biomarker
polarity
not_inferred
span
end
931
end exclusive
true
exact text
HER2 positive locally advanced or metastatic
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
887
context exact
treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment.
kind
stage_or_setting
polarity
not_inferred
span
end
952
end exclusive
true
exact text
locally advanced or metastatic breast cancer follow
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
901
context exact
• in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment.
kind
regimen
polarity
not_inferred
span
end
917
end exclusive
true
exact text
in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
738

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 976
end exclusive: true
exact text: • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment.
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 736

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA207103

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1184
end exclusive: true
exact text: r without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advan
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 777

current approval status

not_reconciled

duplicate text group

dup-7e032e46d5278e1574d2

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-312fff73d246059657f0

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 984
end exclusive: true
exact text: ( 1.2 )
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 977

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

NDA207103

brand names

Ibrance

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1436
end exclusive: true
exact text: t pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2 positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 785

current approval status

not_reconciled

duplicate text group

dup-9e18d9ecdb31b788418e

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-d5d4ce408531ef2cba08

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

end: 1048
end exclusive: true
exact text: is indicated
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1036

qualifier mentions

context exact
tic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
1084
end exclusive
true
exact text
adult patients
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1070
context exact
1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hor
kind
biomarker
polarity
not_inferred
span
end
1033
end exclusive
true
exact text
HER2-Negative Metastatic Breast Cancer IBRAN
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
989
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
kind
biomarker
polarity
not_inferred
span
end
1208
end exclusive
true
exact text
HER2)-negative advanced or metastatic breast
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1164
context exact
1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (
kind
stage_or_setting
polarity
not_inferred
span
end
1048
end exclusive
true
exact text
Metastatic Breast Cancer IBRANCE is indicated
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1003
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
kind
stage_or_setting
polarity
not_inferred
span
end
1222
end exclusive
true
exact text
advanced or metastatic breast cancer in com
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1179
context exact
ptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
kind
regimen
polarity
not_inferred
span
end
1236
end exclusive
true
exact text
in combination with:
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1216

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1236
end exclusive: true
exact text: 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 985

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · unclassified context

application numbers

NDA207103

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1500
end exclusive: true
exact text: s indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1037

current approval status

not_reconciled

duplicate text group

dup-f2728282bb51dff46fe4

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-fb679cbaa47b814d8560

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1300
end exclusive: true
exact text: • an aromatase inhibitor as initial endocrine-based therapy; or
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1237

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · positive indication candidate

application numbers

NDA207103

brand names

Ibrance

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1580
end exclusive: true
exact text: eptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or meta
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1101

current approval status

not_reconciled

duplicate text group

dup-8bbeac32d49bfd397245

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-2016b983e103c6cbfb2c

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

end: 1048
end exclusive: true
exact text: is indicated
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1036

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1380
end exclusive: true
exact text: • fulvestrant in patients with disease progression following endocrine therapy.
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1301

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 11 · positive indication candidate

application numbers

NDA207103

brand names

Ibrance

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1913
end exclusive: true
exact text: vanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1181

current approval status

not_reconciled

duplicate text group

dup-d5a915c49b7b30a45461

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-246039447039313c536a

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

end: 1401
end exclusive: true
exact text: is indicated
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1389

qualifier mentions

context exact
nation with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER
kind
age
polarity
not_inferred
span
end
1484
end exclusive
true
exact text
adult patients
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1470
context exact
r the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic
kind
biomarker
polarity
not_inferred
span
end
1526
end exclusive
true
exact text
PIK3CA -mutated
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1511
context exact
nts with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected
kind
biomarker
polarity
not_inferred
span
end
1554
end exclusive
true
exact text
HER2-negative
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1541
context exact
A -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurren
kind
biomarker
polarity
not_inferred
span
end
1600
end exclusive
true
exact text
metastatic breast cancer
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1576
context exact
ine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurren
kind
stage_or_setting
polarity
not_inferred
span
end
1600
end exclusive
true
exact text
locally advanced or metastatic breast cancer
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1556
context exact
uthorized test, following recurrence on or after completing adjuvant endocrine therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1712
end exclusive
true
exact text
adjuvant endocrine therapy
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1686
context exact
IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test,
kind
regimen
polarity
not_inferred
span
end
1581
end exclusive
true
exact text
in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metas
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1402

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 1713
end exclusive: true
exact text: IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy.
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1381

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 12 · positive indication candidate

application numbers

NDA207103

brand names

Ibrance

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2016
end exclusive: true
exact text: 3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1514

current approval status

not_reconciled

duplicate text group

dup-2e99f72d8c93945ccf45

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-61d8fdbdeeca584a249c

label id

7dcc9b87-0aa4-4a00-aced-96be3553e8ac

positive predicate support span

end: 1777
end exclusive: true
exact text: is indicated
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1765

qualifier mentions

context exact
mab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metasta
kind
age
polarity
not_inferred
span
end
1908
end exclusive
true
exact text
adult patients
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1894
context exact
1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or wit
kind
biomarker
polarity
not_inferred
span
end
1762
end exclusive
true
exact text
HER2-Positive Metastatic Breast Cancer IBRAN
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1718
context exact
e maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
kind
biomarker
polarity
not_inferred
span
end
1971
end exclusive
true
exact text
HER2-positive locally advanced or metastatic
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1927
context exact
1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab
kind
stage_or_setting
polarity
not_inferred
span
end
1777
end exclusive
true
exact text
Metastatic Breast Cancer IBRANCE is indicated
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1732
context exact
treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
kind
stage_or_setting
polarity
not_inferred
span
end
1992
end exclusive
true
exact text
locally advanced or metastatic breast cancer follow
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1941
context exact
HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
kind
regimen
polarity
not_inferred
span
end
1957
end exclusive
true
exact text
in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced
label id
7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start
1778

regulatory links

schema version

0.1.0

source batch sha256

a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef

source defined aliases

source span

end: 2016
end exclusive: true
exact text: 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
label id: 7dcc9b87-0aa4-4a00-aced-96be3553e8ac
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 493dbca73be6ad787976be313aa10db4112caa832125caa73d11b56974c34a43
start: 1714

source url

https://api.fda.gov/drug/label.json?search=id%3A%227dcc9b87-0aa4-4a00-aced-96be3553e8ac%22

spl effective date

2026-07-02

spl set id

e0e6412f-50b4-4fd4-9364-62818d121a07

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice